We observed no significant loss in body weight in mice treated with the different regimens, as shown in Figure S2D. The individual tumor sizes (fold-change) and ORR, as shown in Figure S2E, indicated that treatment with anti-PD-1 antibody group achieved 25% ORR, anti-PD-1 antibody combined with cabozantinib plus celecoxib achieved 57% ORR, and anti-PD-1 antibody (2.5 mg/kg) combined with cabozantinib plus chidamide-k30 achieved 100% ORR. This evidence concerns the gene PDCD1 and neoplasm.